Emma Asma Cornwall
All posts from Emma Asma Cornwall
Emma Asma Cornwall in Gainers & Losers,

​Eli Lilly is a decent buy

Eli Lilly is up on today's session after JPMorgan Chase upgraded the drug maker to "overweight" from "neutral," saying new products are likely to drive earnings higher in 2017 and beyond. Well, although this is not the best choice in pharma industry right now, Eli Lilly is a fairly decent investment.

Stock price broke through a falling channel today and has more room for upward move: